Collaboration And LicensingEntera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.
Funding And Financial SupportOPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.
Market OpportunityThe collaboration with OPKO provides access to a promising anti-obesity candidate, funding, and favorable economics in a large and lucrative market.